Free Trial
NYSEAMERICAN:IBIO

iBio (IBIO) Stock Price, News & Analysis

$0.92 +0.07 (+8.50%)
As of 04/25/2025 04:00 PM Eastern

About iBio Stock (NYSEAMERICAN:IBIO)

Key Stats

Today's Range
$0.81
$0.93
50-Day Range
$0.70
$6.41
52-Week Range
$0.64
$6.89
Volume
520,218 shs
Average Volume
686,663 shs
Market Capitalization
$3.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

iBio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

IBIO MarketRank™: 

iBio scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for iBio.

  • Percentage of Shares Shorted

    9.94% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently decreased by 20.90%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    iBio does not currently pay a dividend.

  • Dividend Growth

    iBio does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.94% of the float of iBio has been sold short.
  • Short Interest Ratio / Days to Cover

    iBio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in iBio has recently decreased by 20.90%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for iBio this week, compared to 0 articles on an average week.
  • Search Interest

    10 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, iBio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 1.12% of the stock of iBio is held by insiders.

  • Percentage Held by Institutions

    Only 7.90% of the stock of iBio is held by institutions.

  • Read more about iBio's insider trading history.
Receive IBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for iBio and its competitors with MarketBeat's FREE daily newsletter.

IBIO Stock News Headlines

iBio announces data from non-human primate PK study of IBIO-600
iBio to transfer listing to Nasdaq from NYSE
DOGE officially begins retirement transformation
Elon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retirement" process . This fired the starting gun on the biggest economic transformation in American history.
IBio Expands Cardiometabolic And Obesity Program
See More Headlines

IBIO Stock Analysis - Frequently Asked Questions

iBio's stock was trading at $2.42 on January 1st, 2025. Since then, IBIO stock has decreased by 62.0% and is now trading at $0.9190.
View the best growth stocks for 2025 here
.

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Mesoblast (MESO), Mobileye Global (MBLY), KULR Technology Group (KULR), IonQ (IONQ), Guardforce AI (GFAI), Fastly (FSLY) and Exscientia (EXAI).

Company Calendar

Today
4/26/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:IBIO
Employees
100
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-65,010,000.00
Pretax Margin
-41,546.00%

Debt

Sales & Book Value

Annual Sales
$2.38 million
Price / Cash Flow
N/A
Book Value
$15.15 per share
Price / Book
0.06

Miscellaneous

Free Float
3,445,000
Market Cap
$3.20 million
Optionable
N/A
Beta
-3.77
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSEAMERICAN:IBIO) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners